Regular Hours
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| Valuation Estimation |
|
EPS (Current/Estimated)
-0.80/0.51
|
|
Enterprise Value
422.77M
|
| Balance Sheet |
|
Book Value Per Share
-0.36
|
| Cash Flow |
|
Cash Flow Yield
--
|
| Income Statement |
|
Total Revenue
297.18M
|
|
Operating Revenue Per Share
2.85
|
|
Industry Comparison
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
|
Business Description
|
|||
| Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia. |

4.01 
